Enorama Pharma Sues FDA Over Nicotine Pouch PMTA Rules: What You Need to Know

Enorama Pharma Inc. has filed a federal lawsuit against the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services challenging how the agency is regulating nicotine pouches — a rapidly-growing segment of oral nicotine products. The case, ENORAMA PHARMA INC. v. U.S. FOOD AND DRUG ADMINISTRATION, No. 1:2026cv00502, was filed on February 17, 2026 in the U.S. District Court for the District of Columbia.  

The Core of the Dispute: PMTA Requirements for Nicotine Pouches 

At the center of the lawsuit is the FDA’s interpretation and application of the Premarket Tobacco Product Application (PMTA) process under the Tobacco Control Act. Any company that wants to market a new tobacco product — including nicotine pouches — must submit a PMTA and receive FDA authorization before legally selling the product in the United States.  

What Enorama Claims 

According to the complaint, Enorama alleges that: 

• The FDA’s 2021 PMTA rule imposes the same clinical and non-clinical study requirements on nicotine pouches as on traditional combustible tobacco products — despite major differences in risk profile and product design.  
• The agency refused to file Enorama’s PMTAs for substantive review based on these requirements, jeopardizing the company’s ability to remain on the market.  
• The FDA violated the Regulatory Flexibility Act (RFA) by adopting the 2021 rule without sufficiently analyzing its economic impact on small businesses.  
• The agency also violated the Administrative Procedure Act (APA) by applying the PMTA requirements in an “arbitrary and capricious” manner.  

Why This Lawsuit Matters 

1. Cost and Competitive Barriers 

Industry coverage reports note that Enorama claims the FDA’s PMTA requirements have driven up compliance costs dramatically. While FDA estimated bundled application costs between roughly $181,686 and $2 million, Enorama asserts that actual costs for its nicotine pouch applications fall between $3 million and $15 million or more — a level that could push smaller manufacturers out of the market.  

This dispute underscores broader industry concern that FDA’s current PMTA standards — originally designed for combustible products — may not be well-suited for lower-risk alternatives like tobacco-free nicotine pouches.  

2. Allegations of Unequal Treatment 

Enorama’s complaint also alleges that larger competitors have received more favorable regulatory treatment. Specifically, some established brands have been authorized while Enorama received a Refuse-to-File (RTF) letter — effectively blocking review of its applications. Enorama is seeking judicial relief and may pursue a preliminary injunction to stop the FDA from enforcing these PMTA rejections.  

3. Broader Implications for the Nicotine Pouch Market 

Nicotine pouches have emerged as a significant option for adult nicotine users and potential smoking cessation alternatives. A legal decision in this case could reshape the FDA’s approach to regulating this product category, with potential ripple effects on: 

• PMTA standards for future nicotine products 
• Market access for small and mid-sized manufacturers 
• FDA’s broader tobacco and nicotine regulatory authority 

Industry analysts and legal observers will be watching closely to see how the court interprets the agency’s responsibilities under the RFA and APA.  

What’s Next in the Case 

Enorama’s motion to partially seal its complaint — to protect proprietary business information — has already been granted by the court.  

Further developments will likely involve briefing on the merits of the claims, potential motions for preliminary injunctions, and whether the FDA will defend the challenged regulatory standards. 

Conclusion 

The Enorama Pharma lawsuit against the FDA highlights ongoing tensions in nicotine product regulation and raises critical questions about how federal law should balance public health protections with market access and fairness for emerging product categories like nicotine pouches. As this litigation unfolds, its outcomes could have lasting policy and commercial implications across the tobacco and nicotine landscape.